Current and emerging treatment options for premature ejaculation.
Journal
Nature reviews. Urology
ISSN: 1759-4820
Titre abrégé: Nat Rev Urol
Pays: England
ID NLM: 101500082
Informations de publication
Date de publication:
11 2022
11 2022
Historique:
accepted:
20
07
2022
pubmed:
26
8
2022
medline:
5
11
2022
entrez:
25
8
2022
Statut:
ppublish
Résumé
Premature ejaculation (PE) is a prevalent male sexual dysfunction. Current standard treatment regimens include behavioural therapies, topical anaesthetics, dapoxetine and other selective serotonin reuptake inhibitors (SSRIs). Most of the pharmacotherapeutic options target neurotransmitters (such as serotonin and oxytocin) that have a role in the ejaculation mechanism. However, these treatments are mildly effective and only provide a temporary delay in the ejaculation latency time, and PE recurs when the treatment is stopped. Thus, a treatment for PE is urgently needed and research is ongoing to find the ideal PE therapy. The efficacy and safety of topical anaesthetics and SSRIs in delaying ejaculation have been confirmed in many well-designed controlled trials. Both preclinical and clinical studies on new-generation SSRIs are ongoing. Moreover, promising results came from clinical trials in which the efficacy of on-demand PE therapies targeting neurotransmitters other than serotonin, such as α1-adrenoceptor antagonists and oxytocin antagonists, was assessed. Surgical intervention and neuromodulation have been proposed as potential treatment options for PE; however, current PE guidelines do not recommend these treatments owing to safety concerns.
Identifiants
pubmed: 36008555
doi: 10.1038/s41585-022-00639-5
pii: 10.1038/s41585-022-00639-5
doi:
Substances chimiques
Serotonin
333DO1RDJY
Anesthetics, Local
0
Oxytocin
50-56-6
Serotonin Uptake Inhibitors
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
659-680Informations de copyright
© 2022. Springer Nature Limited.
Références
American Psychiatric Association. Diagnostic and statistical manual of mental disorders: DSM-5 5th edn (American Psychiatric Association, 2013).
Parnham, A. & Serefoglu, E. C. Classification and definition of premature ejaculation. Transl. Androl. Urol. 5, 416–423 (2016).
pubmed: 27652214
pmcid: 5001991
doi: 10.21037/tau.2016.05.16
Serefoglu, E. C. et al. An evidence-based unified definition of lifelong and acquired premature ejaculation: report of the second International Society for Sexual Medicine Ad Hoc Committee for the Definition of Premature Ejaculation. J. Sex. Med. 11, 1423–1441 (2014).
pubmed: 24848805
doi: 10.1111/jsm.12524
Waldinger, M. D. & Schweitzer, D. H. Changing paradigms from a historical DSM-III and DSM-IV view toward an evidence-based definition of premature ejaculation. Part II — proposals for DSM-V and ICD-11. J. Sex. Med. 3, 693–705 (2006).
pubmed: 16839326
doi: 10.1111/j.1743-6109.2006.00276.x
Serefoglu, E. C. et al. The comparison of premature ejaculation assessment questionnaires and their sensitivity for the four premature ejaculation syndromes: results from the Turkish Society of Andrology sexual health survey. J. Sex. Med. 8, 1177–1185 (2011).
pubmed: 21269396
doi: 10.1111/j.1743-6109.2010.02183.x
Serefoglu, E. C., Cimen, H. I., Atmaca, A. F. & Balbay, M. D. The distribution of patients who seek treatment for the complaint of ejaculating prematurely according to the four premature ejaculation syndromes. J. Sex. Med. 7, 810–815 (2010).
pubmed: 19912501
doi: 10.1111/j.1743-6109.2009.01570.x
Serefoglu, E. C. et al. Prevalence of the complaint of ejaculating prematurely and the four premature ejaculation syndromes: results from the Turkish Society of Andrology Sexual Health Survey. J. Sex. Med. 8, 540–548 (2011).
pubmed: 21054799
doi: 10.1111/j.1743-6109.2010.02095.x
Porst, H. et al. The premature ejaculation prevalence and attitudes (PEPA) survey: prevalence, comorbidities, and professional help-seeking. Eur. Urol. 51, 816–823 (2007).
pubmed: 16934919
doi: 10.1016/j.eururo.2006.07.004
Laumann, E. O., Paik, A. & Rosen, R. C. Sexual dysfunction in the United States: prevalence and predictors. JAMA 281, 537–544 (1999).
pubmed: 10022110
doi: 10.1001/jama.281.6.537
Tang, W. S. & Khoo, E. M. Prevalence and correlates of premature ejaculation in a primary care setting: a preliminary cross-sectional study. J. Sex. Med. 8, 2071–2078 (2011).
pubmed: 21492404
doi: 10.1111/j.1743-6109.2011.02280.x
McMahon, C. G., Lee, G., Park, J. K. & Adaikan, P. G. Premature ejaculation and erectile dysfunction prevalence and attitudes in the Asia-Pacific region. J. Sex. Med. 9, 454–465 (2012).
pubmed: 22023395
doi: 10.1111/j.1743-6109.2011.02507.x
Saitz, T. R. & Serefoglu, E. C. The epidemiology of premature ejaculation. Transl. Androl. Urol. 5, 409–415 (2016).
pubmed: 27652213
pmcid: 5001986
doi: 10.21037/tau.2016.05.11
Althof, S. E. et al. An update of the International Society of Sexual Medicine’s Guidelines for the diagnosis and treatment of premature ejaculation (PE). Sex. Med. 2, 60–90 (2014).
pubmed: 25356302
pmcid: 4184677
doi: 10.1002/sm2.28
Waldinger, M. D. et al. A multinational population survey of intravaginal ejaculation latency time. J. Sex. Med. 2, 492–497 (2005).
pubmed: 16422843
doi: 10.1111/j.1743-6109.2005.00070.x
Waldinger, M. D., McIntosh, J. & Schweitzer, D. H. A five-nation survey to assess the distribution of the intravaginal ejaculatory latency time among the general male population. J. Sex. Med. 6, 2888–2895 (2009).
pubmed: 19627471
doi: 10.1111/j.1743-6109.2009.01392.x
Kempeneers, P. et al. Functional and psychological characteristics of Belgian men with premature ejaculation and their partners. Arch. Sex. Behav. 42, 51–66 (2013).
pubmed: 22695640
doi: 10.1007/s10508-012-9958-y
Gopalakrishna, A. et al. Characteristics of men who are bothered by rapid ejaculation: results from clinical intake surveys. Int. J. Impot. Res. 33, 369–375 (2021).
pubmed: 32332929
doi: 10.1038/s41443-020-0277-x
Saitz, T. R. & Serefoglu, E. C. Advances in understanding and treating premature ejaculation. Nat. Rev. Urol. 12, 629–640 (2015).
pubmed: 26502991
doi: 10.1038/nrurol.2015.252
Culha, M. G., Tuken, M., Gonultas, S., Cakir, O. O. & Serefoglu, E. C. Frequency of etiological factors among patients with acquired premature ejaculation: prospective, observational, single-center study. Int. J. Impot. Res. https://doi.org/10.1038/s41443-019-0188-x (2019).
doi: 10.1038/s41443-019-0188-x
pubmed: 31477853
McMahon, C. G., Jannini, E. A., Serefoglu, E. C. & Hellstrom, W. J. The pathophysiology of acquired premature ejaculation. Transl. Androl. Urol. 5, 434–449 (2016).
pubmed: 27652216
pmcid: 5001985
doi: 10.21037/tau.2016.07.06
Waldinger, M. D. The pathophysiology of lifelong premature ejaculation. Transl. Androl. Urol. 5, 424–433 (2016).
pubmed: 27652215
pmcid: 5001987
doi: 10.21037/tau.2016.06.04
Donatucci, C. F. Etiology of ejaculation and pathophysiology of premature ejaculation. J. Sex. Med. 3, 303–308 (2006).
pubmed: 16939474
doi: 10.1111/j.1743-6109.2006.00305.x
Guo, L. et al. Significance of penile hypersensitivity in premature ejaculation. Sci. Rep. 7, 10441 (2017).
pubmed: 28874780
pmcid: 5585329
doi: 10.1038/s41598-017-09155-8
Corona, G. et al. Interplay between premature ejaculation and erectile dysfunction: a systematic review and meta-analysis. J. Sex. Med. 12, 2291–2300 (2015).
pubmed: 26552599
doi: 10.1111/jsm.13041
Fu, X. et al. Association between lifelong premature ejaculation and polymorphism of tryptophan hydroxylase 2 gene in the Han population. Sex. Med. 8, 223–229 (2020).
pubmed: 32169437
pmcid: 7261684
doi: 10.1016/j.esxm.2020.02.004
Janssen, P. K., Schaik, R., Olivier, B. & Waldinger, M. D. The 5-HT2C receptor gene Cys23Ser polymorphism influences the intravaginal ejaculation latency time in Dutch Caucasian men with lifelong premature ejaculation. Asian J. Androl. 16, 607–610 (2014).
pubmed: 24799636
pmcid: 4104091
doi: 10.4103/1008-682X.126371
Salem, A. M., Kamel, I. I., Rashed, L. A. & GamalEl Din, S. F. Effects of paroxetine on intravaginal ejaculatory latency time in Egyptian patients with lifelong premature ejaculation as a function of serotonin transporter polymorphism. Int. J. Impot. Res. 29, 7–11 (2017).
pubmed: 27679962
doi: 10.1038/ijir.2016.36
Eltonsi, T. K., Tawfik, T. M., Rashed, L. A., GamalEl Din, S. F. & Mahmoud, M. A. Study of the link between dopamine transporter gene polymorphisms and response to paroxetin and escitalopram in patients with lifelong premature ejaculation. Int. J. Impot. Res. 29, 235–239 (2017).
pubmed: 28904397
doi: 10.1038/ijir.2017.29
Abu El-Hamd, M. & Farah, A. Possible role of serum testosterone, gonadotropins and prolactin in patients with premature ejaculation. Andrologia https://doi.org/10.1111/and.12808 (2018).
doi: 10.1111/and.12808
pubmed: 30411390
Cihan, A. et al. The relationship between premature ejaculation and hyperthyroidism. J. Urol. 181, 1273–1280 (2009).
pubmed: 19185321
doi: 10.1016/j.juro.2008.10.150
Sihotang, R. C. et al. Premature ejaculation in patients with lower urinary tract symptoms: a systematic review. Int. J. Impot. Res. 33, 516–524 (2021).
pubmed: 32393845
doi: 10.1038/s41443-020-0298-5
Shamloul, R. & el-Nashaar, A. Chronic prostatitis in premature ejaculation: a cohort study in 153 men. J. Sex. Med. 3, 150–154 (2006).
pubmed: 16409229
doi: 10.1111/j.1743-6109.2005.00107.x
Waldinger, M. D., Zwinderman, A. H., Schweitzer, D. H. & Olivier, B. Relevance of methodological design for the interpretation of efficacy of drug treatment of premature ejaculation: a systematic review and meta-analysis. Int. J. Impot. Res. 16, 369–381 (2004).
pubmed: 14961051
doi: 10.1038/sj.ijir.3901172
Waldinger, M. D. Towards evidence-based drug treatment research on premature ejaculation: a critical evaluation of methodology. Int. J. Impot. Res. 15, 309–313 (2003).
pubmed: 14562129
doi: 10.1038/sj.ijir.3901023
McMahon, C. G. & Porst, H. Oral agents for the treatment of premature ejaculation: review of efficacy and safety in the context of the recent International Society for Sexual Medicine criteria for lifelong premature ejaculation. J. Sex. Med. 8, 2707–2725 (2011).
pubmed: 21771283
doi: 10.1111/j.1743-6109.2011.02386.x
Xia, J.-D., Han, Y.-F., Zhou, L.-H., Chen, Y. & Dai, Y.-T. Efficacy and safety of local anaesthetics for premature ejaculation: a systematic review and meta-analysis. Asian J. Androl. 15, 497–502 (2013).
pubmed: 23708465
pmcid: 3739226
doi: 10.1038/aja.2012.174
Salonia, A. et al. Acceptance of and discontinuation rate from paroxetine treatment in patients with lifelong premature ejaculation. J. Sex. Med. 6, 2868–2877 (2009).
pubmed: 19656274
doi: 10.1111/j.1743-6109.2009.01404.x
Boeri, L., Pozzi, E., Fallara, G., Montorsi, F. & Salonia, A. Real-life use of the eutectic mixture lidocaine/prilocaine spray in men with premature ejaculation. Int. J. Impot. Res. https://doi.org/10.1038/s41443-021-00424-9 (2021).
doi: 10.1038/s41443-021-00424-9
pubmed: 34853436
Abu El-Hamd, M. Effectiveness and tolerability of lidocaine 5% spray in the treatment of lifelong premature ejaculation patients: a randomized single-blind placebo-controlled clinical trial. Int. J. Impot. Res. 33, 96–101 (2021).
pubmed: 31896832
doi: 10.1038/s41443-019-0225-9
Mondaini, N. et al. Dapoxetine treatment in patients with lifelong premature ejaculation: the reasons of a “Waterloo”. Urology 82, 620–624 (2013).
pubmed: 23987156
doi: 10.1016/j.urology.2013.05.018
Clement, P. & Giuliano, F. Physiology and pharmacology of ejaculation. Basic. Clin. Pharmacol. Toxicol. 119 (Suppl. 3), 18–25 (2016).
pubmed: 26709195
doi: 10.1111/bcpt.12546
Giuliano, F. & Clement, P. Neuroanatomy and physiology of ejaculation. Annu. Rev. Sex. Res. 16, 190–216 (2005).
pubmed: 16913292
Truitt, W. A. & Coolen, L. M. Identification of a potential ejaculation generator in the spinal cord. Science 297, 1566–1569 (2002).
pubmed: 12202834
doi: 10.1126/science.1073885
Veening, J. & Coolen, L. Neural mechanisms of sexual behavior in the male rat: emphasis on ejaculation-related circuits. Pharmacol. Biochem. Behav. 121, 170–183 (2014).
pubmed: 24368305
doi: 10.1016/j.pbb.2013.12.017
Levin, R. J. The mechanisms of human ejaculation — a critical analysis. Sex. Relatsh. Ther. 20, 123–131 (2005).
doi: 10.1080/14681990500037212
Alwaal, A., Breyer, B. N. & Lue, T. F. Normal male sexual function: emphasis on orgasm and ejaculation. Fertil. Steril. 104, 1051–1060 (2015).
pubmed: 26385403
pmcid: 4896089
doi: 10.1016/j.fertnstert.2015.08.033
McMahon, C. G. et al. Disorders of orgasm and ejaculation in men. J. Sex. Med. 1, 58–65 (2004).
pubmed: 16422984
doi: 10.1111/j.1743-6109.2004.10109.x
Missale, C., Nash, S. R., Robinson, S. W., Jaber, M. & Caron, M. G. Dopamine receptors: from structure to function. Physiol. Rev. 78, 189–225 (1998).
pubmed: 9457173
doi: 10.1152/physrev.1998.78.1.189
Neve, K. A. & Neve, R. L. in The Dopamine Receptors 27–76 (Springer, 1997).
Neve, K. A., Seamans, J. K. & Trantham-Davidson, H. Dopamine receptor signaling. J. Recept. Signal Transduct. Res. 24, 165–205 (2004).
pubmed: 15521361
doi: 10.1081/RRS-200029981
Paglietti, E., Quarantotti, B. P., Mereu, G. & Gessa, G. Apomorphine and L-DOPA lower ejaculation threshold in the male rat. Physiol. Behav. 20, 559–562 (1978).
pubmed: 684090
doi: 10.1016/0031-9384(78)90247-0
Pfaus, J. G. & Phillips, A. G. Role of dopamine in anticipatory and consummatory aspects of sexual behavior in the male rat. Behav. Neurosci. 105, 727 (1991).
pubmed: 1840012
doi: 10.1037/0735-7044.105.5.727
Berger, M., Gray, J. A. & Roth, B. L. The expanded biology of serotonin. Annu. Rev. Med. 60, 355–366 (2009).
pubmed: 19630576
pmcid: 5864293
doi: 10.1146/annurev.med.60.042307.110802
Barnes, N. M. et al. International Union of Basic and Clinical Pharmacology. CX. Classification of Receptors for 5-hydroxytryptamine; Pharmacology and Function. Pharmacol. Rev. 73, 310–520 (2021).
pubmed: 33370241
pmcid: 7770494
doi: 10.1124/pr.118.015552
Giuliano, F. & Clément, P. Physiology of ejaculation: emphasis on serotonergic control. Eur. Urol. 48, 408–417 (2005).
pubmed: 15996810
doi: 10.1016/j.eururo.2005.05.017
Barnes, N. M. & Sharp, T. A review of central 5-HT receptors and their function. Neuropharmacology 38, 1083–1152 (1999).
pubmed: 10462127
doi: 10.1016/S0028-3908(99)00010-6
Hillegaart, V. & Ahlenius, S. Facilitation and inhibition of male rat ejaculatory behaviour by the respective 5-HT1A and 5-HT1B receptor agonists 8-OH-DPAT and anpirtoline, as evidenced by use of the corresponding new and selective receptor antagonists NAD-299 and NAS-181. Br. J. Pharmacol. 125, 1733–1743 (1998).
pubmed: 9886765
pmcid: 1565750
doi: 10.1038/sj.bjp.0702239
Garcia-Garcia, A. L., Newman-Tancredi, A. & Leonardo, E. D. 5-HT
pubmed: 24337875
doi: 10.1007/s00213-013-3389-x
Esquivel-Franco, D. C., de Boer, S. F., Waldinger, M., Olivier, B. & Olivier, J. D. A. Pharmacological studies on the role of 5-HT1A receptors in male sexual behavior of wildtype and serotonin transporter knockout rats. Front. Behav. Neurosci. 14, 40 (2020).
pubmed: 32296313
pmcid: 7136541
doi: 10.3389/fnbeh.2020.00040
Waldinger, M. D. The neurobiological approach to premature ejaculation. J. Urol. 168, 2359–2367 (2002).
pubmed: 12441918
doi: 10.1016/S0022-5347(05)64146-8
Lasker, G. F., Halis, F. & Gokce, A. Selective serotonin reuptake inhibitors for premature ejaculation: review of erectile and ejaculatory side effects. Curr. Drug Saf. 9, 118–126 (2014).
pubmed: 24446888
doi: 10.2174/1574886309666140120095846
Waldinger, M. D., Rietschel, M., Nöthen, M. M., Hengeveld, M. W. & Olivier, B. Familial occurrence of primary premature ejaculation. Psychiatr. Genet. 8, 37 (1998).
pubmed: 9564687
doi: 10.1097/00041444-199800810-00007
Jern, P. et al. Premature and delayed ejaculation: genetic and environmental effects in a population-based sample of Finnish twins. J. Sex. Med. 4, 1739–1749 (2007).
pubmed: 17888070
doi: 10.1111/j.1743-6109.2007.00599.x
Janssen, P. K. et al. Serotonin transporter promoter region (5-HTTLPR) polymorphism is associated with the intravaginal ejaculation latency time in Dutch men with lifelong premature ejaculation. J. Sex. Med. 6, 276–284 (2009).
pubmed: 19170855
doi: 10.1111/j.1743-6109.2008.01033.x
Janssen, P. K., van Schaik, R., Zwinderman, A. H., Olivier, B. & Waldinger, M. D. The 5-HT
pubmed: 24440118
doi: 10.1016/j.pbb.2014.01.004
Waldinger, M. D. Ejaculatio praecox, erectio praecox, and detumescentia praecox as symptoms of a hypertonic state in lifelong premature ejaculation: a new hypothesis. Pharmacol. Biochem. Behav. 121, 189–194 (2014).
pubmed: 24333546
doi: 10.1016/j.pbb.2013.12.004
Ehrentheil, O. F. A case of premature ejaculation in Greek mythology. J. Sex. Res. 10, 128–131 (1974).
doi: 10.1080/00224497409550839
Abraham, K. Über ejaculatio praecox. Int. Z. Psychoanal. 4, 171–186 (1917).
Gross, S. W. & History of Medicine Collections (Duke University). A Practical Treatise on Impotence, Sterility, and Allied Disorders of the Male Sexual Organs (H.C. Lea’s Son, 1881).
Waldinger, M. D. The need for a revival of psychoanalytic investigations into premature ejaculation. J. Mens Health Gend. 3, 390–396 (2006).
doi: 10.1016/j.jmhg.2006.08.008
Schapiro, B. Premature ejaculation: a review of 1130 cases. J. Urol. 50, 374–379 (1943).
doi: 10.1016/S0022-5347(17)70462-4
Aycock, L. The medical management of premature ejaculation. J. Urol. 62, 361–361 (1949).
pubmed: 18148290
doi: 10.1016/S0022-5347(17)68934-1
Singh, H. A case of inhibition of ejaculation as a side effect of Mellaril. Am. J. Psychiatry 117, 1041–1042 (1961).
doi: 10.1176/ajp.117.11.1041
Freyhan, F. A. Loss of ejaculation during Mellaril treatment. Am. J. Psychiatry 118, 171–172 (1961).
pubmed: 13701856
doi: 10.1176/ajp.118.2.171
Mellgren, A. Treatment of ejaculatio praecox with thioridazine. Psychother. Psychosom. 15, 454–460 (1967).
doi: 10.1159/000285909
Bennett, D. Treatment of ejaculatio praecox with monoamine-oxidase inhibitors. Lancet 278, 1309 (1961).
doi: 10.1016/S0140-6736(61)91174-6
Rapp, M. S. Two cases of ejaculatory impairment related to phenelzine. Am. J. Psychiatry 136, 1200–1201 (1979).
pubmed: 474812
doi: 10.1176/ajp.136.9.1200
Semans, J. H. Premature ejaculation: a new approach. South. Med. J. 49, 353–358 (1956).
pubmed: 13311629
doi: 10.1097/00007611-195604000-00008
Masters, W. & Johnson, V. Premature ejaculation. Human Sexual Inadequacy (Little, Brown, 92–115 (1970).
Salonia, A. et al. European Association of Urology guidelines on sexual and reproductive health — 2021 update: male sexual dysfunction. Eur. Urol. https://doi.org/10.1016/j.eururo.2021.06.007 (2021).
doi: 10.1016/j.eururo.2021.06.007
pubmed: 34511305
pmcid: 8263124
Eaton, H. Clomipramine (Anafranil) in the treatment of premature ejaculation. J. Int. Med. Res. 1, 432–434 (1973).
doi: 10.1177/030006057300100531
Choi, J. B. et al. Efficacy and safety of on demand clomipramine for the treatment of premature ejaculation: a multicenter, randomized, double-blind, phase III clinical trial. J. Urol. 201, 147–152 (2019).
pubmed: 30086277
doi: 10.1016/j.juro.2018.07.089
Kim, S. W. et al. Tolerability and adequate therapeutic dosage of oral clomipramine for the treatment of premature ejaculation: a randomized, double-blind, placebo-controlled, fixed-dose, parallel-grouped clinical study. Int. J. Impot. Res. 30, 65–70 (2018).
pubmed: 29203842
doi: 10.1038/s41443-017-0011-5
Shilon, M., Paz, G. F. & Homonnai, Z. T. The use of phenoxybenzamine treatment in premature ejaculation. Fertil. Steril. 42, 659–661 (1984).
pubmed: 6541599
doi: 10.1016/S0015-0282(16)48157-4
Homonnai, Z. T., Shilon, M. & Paz, G. F. Phenoxybenzamine — an effective male contraceptive pill. Contraception 29, 479–491 (1984).
pubmed: 6430643
doi: 10.1016/0010-7824(84)90022-2
National Toxicology Program. Phenoxybenzamine hydrochloride. Rep. Carcinog. 12, 344–345 (2011).
Lowe, F. C. Role of the newer alpha, -adrenergic-receptor antagonists in the treatment of benign prostatic hyperplasia-related lower urinary tract symptoms. Clin. Ther. 26, 1701–1713 (2004).
pubmed: 15639685
doi: 10.1016/j.clinthera.2004.11.006
Akin, Y., Gulmez, H., Ates, M., Bozkurt, A. & Nuhoglu, B. Comparison of alpha blockers in treatment of premature ejaculation: a pilot clinical trial. Iran. Red. Crescent Med. J. 15, e13805 (2013).
pubmed: 24693363
pmcid: 3950775
doi: 10.5812/ircmj.13805
Yoon, S. et al. Phenoxybenzamine hydrochloride: Summary Report (University of Maryland Baltimore, 2020).
Waldinger, M. D., Hengeveld, M. W. & Zwinderman, A. H. Paroxetine treatment of premature ejaculation: a double-blind, randomized, placebo-controlled study. Am. J. Psychiatry 151, 1377–1379 (1994).
pubmed: 8067497
doi: 10.1176/ajp.151.9.1377
Mendels, J., Camera, A. & Sikes, C. Sertraline treatment for premature ejaculation. J. Clin. Psychopharmacol. 15, 341–346 (1995).
pubmed: 8830065
doi: 10.1097/00004714-199510000-00006
Kara, H. et al. The efficacy of fluoxetine in the treatment of premature ejaculation: a double-blind placebo controlled study. J. Urol. 156, 1631–1632 (1996).
pubmed: 8863556
doi: 10.1016/S0022-5347(01)65467-3
Ludovico, G. M. et al. Paroxetine in the treatment of premature ejaculation. Br. J. Urol. 77, 881–882 (1996).
pubmed: 8705226
doi: 10.1046/j.1464-410X.1996.02120.x
Kim, S. C. & Seo, K. K. Efficacy and safety of fluoxetine, sertraline and clomipramine in patients with premature ejaculation: a double-blind, placebo controlled study. J. Urol. 159, 425–427 (1998).
pubmed: 9649255
doi: 10.1016/S0022-5347(01)63940-5
Waldinger, M., Hengeveld, M. & Zwinderman, A. Ejaculation-retarding properties of paroxetine in patients with primary premature ejaculation: a double-blind, randomized, dose-response study. Br. J. Urol. 79, 592–595 (1997).
pubmed: 9126089
doi: 10.1046/j.1464-410X.1997.00102.x
McMahon, C. & Touma, K. Treatment of premature ejaculation with paroxetine hydrochloride. Int. J. Impot. Res. 11, 241–246 (1999).
pubmed: 10553802
doi: 10.1038/sj.ijir.3900415
Waldinger, M. D., Zwinderman, A. H. & Olivier, B. Antidepressants and ejaculation: a double-blind, randomized, placebo-controlled, fixed-dose study with paroxetine, sertraline, and nefazodone. J. Clin. Psychopharmacol. 21, 293–297 (2001).
pubmed: 11386492
doi: 10.1097/00004714-200106000-00007
Waldinger, M. D., Zwinderman, A. H. & Olivier, B. Antidepressants and ejaculation: a double-blind, randomized, fixed-dose study with mirtazapine and paroxetine. J. Clin. Psychopharmacol. 23, 467–470 (2003).
pubmed: 14520123
doi: 10.1097/01.jcp.0000088904.24613.e4
Wang, W.-f, Chang, L., Minhas, S. & Ralph, D. J. Selective serotonin reuptake inhibitors in the treatment of premature ejaculation. Chin. Med. J. 120, 1000–1006 (2007).
pubmed: 17624269
doi: 10.1097/00029330-200706010-00011
Waldinger, M. D., Berendsen, H. H. G., Blok, B. F. M., Olivier, B. & Holstege, G. Premature ejaculation and serotonergic antidepressants-induced delayed ejaculation: the involvement of the serotonergic system. Behav. Brain Res. 92, 111–118 (1998).
pubmed: 9638953
doi: 10.1016/S0166-4328(97)00183-6
Hamilton, C. L. & Cornpropst, J. D. Determination of dapoxetine, an investigational agent with the potential for treating depression, and its mono- and di-desmethyl metabolites in human plasma using column-switching high-performance liquid chromatography. J. Chromatogr. 612, 253–261 (1993).
pubmed: 8468383
doi: 10.1016/0378-4347(93)80171-Y
Pryor, J. L. et al. Efficacy and tolerability of dapoxetine in treatment of premature ejaculation: an integrated analysis of two double-blind, randomised controlled trials. Lancet 368, 929–937 (2006).
pubmed: 16962882
doi: 10.1016/S0140-6736(06)69373-2
McMahon, C. G. et al. Efficacy and safety of dapoxetine for the treatment of premature ejaculation: integrated analysis of results from five phase 3 trials. J. Sex. Med. 8, 524–539 (2011).
pubmed: 21059176
doi: 10.1111/j.1743-6109.2010.02097.x
Lue, T. F. et al. Summary of the recommendations on sexual dysfunctions in men. J. Sex. Med. 1, 6–23 (2004).
pubmed: 16422979
doi: 10.1111/j.1743-6109.2004.10104.x
Chierigo, F. et al. Lower urinary tract symptoms and depressive symptoms among patients presenting for distressing early ejaculation. Int. J. Impot. Res. 32, 207–212 (2020).
pubmed: 31024115
doi: 10.1038/s41443-019-0147-6
Qin, Z. et al. Safety and efficacy characteristics of oral drugs in patients with premature ejaculation: a Bayesian network meta-analysis of randomized controlled trials. Int. J. Impot. Res. 31, 356–368 (2019).
pubmed: 31024113
doi: 10.1038/s41443-019-0146-7
Salonia, A. et al. in European Association of Urology Guidelines: Sexual and Reproductive Health 2020 Edition Presented at the EAU Annual Congress 2020 (European Association of Urology Guidelines Office, 2020).
Sridharan, K., Sivaramakrishnan, G., Sequeira, R. P. & Al-Khaja, K. A. Pharmacological interventions for premature ejaculation: a mixed-treatment comparison network meta-analysis of randomized clinical trials. Int. J. Impot. Res. 30, 215–223 (2018).
pubmed: 29921893
doi: 10.1038/s41443-018-0030-x
Russo, G. I. & Cocci, A. Do we have put a new cornerstone for the treatment of premature ejaculation. Int. J. Impot. Res. 30, 272–273 (2018).
pubmed: 29930264
doi: 10.1038/s41443-018-0031-9
Shechter, A., Lowenstein, L., Serefoglu, E. C. & Reisman, Y. Attitudes of sexual medicine specialists toward premature ejaculation diagnosis and therapy. Sex. Med. 4, e209–e216 (2016).
pubmed: 27346231
pmcid: 5005309
doi: 10.1016/j.esxm.2016.05.001
Towe, M. et al. “Doc, if it were you, what would you do?”: a survey of Men’s Health specialists’ personal preferences regarding treatment modalities. Int. J. Impot. Res. 33, 303–310 (2021).
pubmed: 32205873
doi: 10.1038/s41443-020-0263-3
Moudi, E. & Kasaeeyan, A. A. Comparison between tadalafil plus paroxetine and paroxetine alone in the treatment of premature ejaculation. Nephrourol. Mon. 8, e32286 (2016).
pubmed: 26981497
pmcid: 4780280
doi: 10.5812/numonthly.32286
Gameel, T. A. et al. On-demand use of tramadol, sildenafil, paroxetine and local anaesthetics for the management of premature ejaculation: a randomised placebo-controlled clinical trial. Arab. J. Urol. 11, 392–397 (2013).
pubmed: 26558110
pmcid: 4443019
doi: 10.1016/j.aju.2013.05.003
Safarinejad, M. R. Comparison of dapoxetine versus paroxetine in patients with premature ejaculation: a double-blind, placebo-controlled, fixed-dose, randomized study. Clin. Neuropharmacol. 29, 243–252 (2006).
pubmed: 16960468
doi: 10.1097/01.WNF.0000228210.12194.46
Waldinger, M. D., Schweitzer, D. H. & Olivier, B. On-demand SSRI treatment of premature ejaculation: pharmacodynamic limitations for relevant ejaculation delay and consequent solutions. J. Sex. Med. 2, 121–131 (2005).
pubmed: 16422915
doi: 10.1111/j.1743-6109.2005.20112.x
Waldinger, M. D. Premature ejaculation: definition and drug treatment. Drugs 67, 547–568 (2007).
pubmed: 17352514
doi: 10.2165/00003495-200767040-00005
McMahon, C. G. & Touma, K. Treatment of premature ejaculation with paroxetine hydrochloride as needed: 2 single-blind placebo controlled crossover studies. J. Urol. 161, 1826–1830 (1999).
pubmed: 10332446
doi: 10.1016/S0022-5347(05)68816-7
Waldinger, M. D., Zwinderman, A. H. & Olivier, B. On-demand treatment of premature ejaculation with clomipramine and paroxetine: a randomized, double-blind fixed-dose study with stopwatch assessment. Eur. Urol. 46, 510–515 (2004).
pubmed: 15363569
doi: 10.1016/j.eururo.2004.05.005
Kim, S. W. & Paick, J. S. Short-term analysis of the effects of as needed use of sertraline at 5 PM for the treatment of premature ejaculation. Urology 54, 544–547 (1999).
pubmed: 10475369
doi: 10.1016/S0090-4295(99)00187-9
Modi, N. B. et al. Single-and multiple-dose pharmacokinetics of dapoxetine hydrochloride, a novel agent for the treatment of premature ejaculation. J. Clin. Pharmacol. 46, 301–309 (2006).
pubmed: 16490806
doi: 10.1177/0091270005284850
Andersson, K. E., Mulhall, J. P. & Wyllie, M. G. Pharmacokinetic and pharmacodynamic features of dapoxetine, a novel drug for ‘on-demand’ treatment of premature ejaculation. BJU Int. 97, 311–315 (2006).
pubmed: 16430636
doi: 10.1111/j.1464-410X.2006.05911.x
Xin, Z. C. et al. Penile sensitivity in patients with primary premature ejaculation. J. Urol. 156, 979–981 (1996).
pubmed: 8709378
doi: 10.1016/S0022-5347(01)65677-5
Wyllie, M. G. & Hellstrom, W. J. The link between penile hypersensitivity and premature ejaculation. BJU Int. 107, 452–457 (2011).
pubmed: 20553259
doi: 10.1111/j.1464-410X.2010.09456.x
Berkovitch, M., Keresteci, A. G. & Koren, G. Efficacy of prilocaine-lidocaine cream in treatment of premature ejaculation. J. Urol. 154, 1360–1361 (1995).
pubmed: 7658537
doi: 10.1016/S0022-5347(01)66861-7
Busato, W. & Galindo, C. Topical anaesthetic use for treating premature ejaculation: a double-blind, randomized, placebo-controlled study. BJU Int. 93, 1018–1021 (2004).
pubmed: 15142155
doi: 10.1111/j.1464-410X.2003.04773.x
Dinsmore, W. W. et al. Topical eutectic mixture for premature ejaculation (TEMPE): a novel aerosol-delivery form of lidocaine-prilocaine for treating premature ejaculation. BJU Int. 99, 369–375 (2007).
pubmed: 17129234
doi: 10.1111/j.1464-410X.2006.06583.x
Dinsmore, W. W. & Wyllie, M. G. PSD502 improves ejaculatory latency, control and sexual satisfaction when applied topically 5 min before intercourse in men with premature ejaculation: results of a phase III, multicentre, double-blind, placebo-controlled study. BJU Int. 103, 940–949 (2009).
pubmed: 19245438
doi: 10.1111/j.1464-410X.2009.08456.x
Carson, C. & Wyllie, M. Improved ejaculatory latency, control and sexual satisfaction when PSD502 is applied topically in men with premature ejaculation: results of a phase III, double-blind, placebo-controlled study. J. Sex. Med. 7, 3179–3189 (2010).
pubmed: 20584124
doi: 10.1111/j.1743-6109.2010.01913.x
Martyn-St James, M. et al. Topical anaesthetics for premature ejaculation: a systematic review and meta-analysis. Sex. Health 13, 114–123 (2016).
pubmed: 26599522
doi: 10.1071/SH15042
Dresser, M. et al. Pharmacokinetics of single and multiple escalating doses of dapoxetine in healthy volunteers. Clin. Pharmacol. Ther. 75, P32–P32 (2004).
doi: 10.1016/j.clpt.2003.11.123
Sangkum, P., Badr, R., Serefoglu, E. C. & Hellstrom, W. J. Dapoxetine and the treatment of premature ejaculation. Transl. Androl. Urol. 2, 301–311 (2013).
pubmed: 26816743
pmcid: 4708110
Dresser, M. J. et al. Pharmacokinetics of dapoxetine, a new treatment for premature ejaculation: Impact of age and effects of a high-fat meal. J. Clin. Pharmacol. 46, 1023–1029 (2006).
pubmed: 16920897
doi: 10.1177/0091270006291033
Buvat, J., Tesfaye, F., Rothman, M., Rivas, D. A. & Giuliano, F. Dapoxetine for the treatment of premature ejaculation: results from a randomized, double-blind, placebo-controlled phase 3 trial in 22 countries. Eur. Urol. 55, 957–968 (2009).
pubmed: 19195772
doi: 10.1016/j.eururo.2009.01.025
McMahon, C. G. et al. Efficacy and safety of dapoxetine in men with premature ejaculation and concomitant erectile dysfunction treated with a phosphodiesterase type 5 inhibitor: randomized, placebo-controlled, phase III study. J. Sex. Med. 10, 2312–2325 (2013).
pubmed: 23845016
doi: 10.1111/jsm.12236
Tuken, M., Culha, M. G. & Serefoglu, E. C. Efficacy and safety of dapoxetine/sildenafil combination tablets in the treatment of men with premature ejaculation and concomitant erectile dysfunction-DAP-SPEED Study. Int. J. Impot. Res. 31, 92–96 (2019).
pubmed: 30705437
doi: 10.1038/s41443-019-0122-2
Cappelleri, J. C., Rosen, R. C., Smith, M. D., Mishra, A. & Osterloh, I. H. Diagnostic evaluation of the erectile function domain of the International Index of Erectile Function. Urology 54, 346–351 (1999).
pubmed: 10443736
doi: 10.1016/S0090-4295(99)00099-0
US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT04361305 (2020).
US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT04703127 (2021).
Yan, W. J., Yu, N., Yin, T. L., Zou, Y. J. & Yang, J. A new potential risk factor in patients with erectile dysfunction and premature ejaculation: folate deficiency. Asian J. Androl. 16, 902–906 (2014).
pubmed: 25080932
pmcid: 4236337
doi: 10.4103/1008-682X.135981
Kadihasanoglu, M. et al. Relation between blood vitamin B12 levels with premature ejaculation: case-control study. Andrologia https://doi.org/10.1111/and.12657 (2017).
doi: 10.1111/and.12657
pubmed: 29023916
US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/results/NCT04085354 (2019).
Verze, P. et al. Comparison of treatment of emergent adverse events in men with premature ejaculation treated with dapoxetine and alternate oral treatments: results from a large multinational observational trial. J. Sex. Med. 13, 194–199 (2016).
pubmed: 26805941
doi: 10.1016/j.jsxm.2015.12.017
Rosen, R. C. et al. Poster 1169: treatment of premature ejaculation (PE) with dapoxetine (DPX) is not associated with suicidality. J. Urol. 177 (Suppl. 4), 385–386 (2007).
doi: 10.1016/S0022-5347(18)31383-1
Giuliano, F. 5-Hydroxytryptamine in premature ejaculation: opportunities for therapeutic intervention. Trends Neurosci. 30, 79–84 (2007).
pubmed: 17169440
doi: 10.1016/j.tins.2006.12.002
Olivier, B., Van Oorschot, R. & Waldinger, M. Serotonin, serotonergic receptors, selective serotonin reuptake inhibitors and sexual behaviour. Int. Clin. Psychopharmacol. 13, S9–S14 (1998).
pubmed: 9728669
doi: 10.1097/00004850-199807006-00003
Biri, H. et al. Sertraline in the treatment of premature ejaculation: a double-blind placebo controlled study. Int. Urol. Nephrol. 30, 611–615 (1998).
pubmed: 9934807
doi: 10.1007/BF02550555
Mcmahon, C. G. Treatment of premature ejaculation with sertraline hydrochloride: a single-blind placebo controlled crossover study. J. Urol. 159, 1935–1938 (1998).
pubmed: 9598491
doi: 10.1016/S0022-5347(01)63201-4
McMahon, C. Treatment of premature ejaculation with sertraline hydrochloride. Int. J. Impot. Res. 10, 181–184 (1998).
pubmed: 9788108
doi: 10.1038/sj.ijir.3900344
Haensel, S., Klem, T., Hop, W. C. & Slob, A. K. Fluoxetine and premature ejaculation: a double-blind, crossover, placebo-controlled study. J. Clin. Psychopharmacol. 18, 72–77 (1998).
pubmed: 9472846
doi: 10.1097/00004714-199802000-00012
Yilmaz, U., Tatlisen, A., Turan, H., Arman, F. & Ekmekcioglu, O. The effects of fluoxetine on several neurophysiological variables in patients with premature ejaculation. J. Urol. 161, 107–111 (1999).
pubmed: 10037380
doi: 10.1016/S0022-5347(01)62078-0
Lee, H. S., Song, D. H., Kim, C.-H. & Choi, H. K. An open clinical trial of fluoxetine in the treatment of premature ejaculation. J. Clin. Psychopharmacol. 16, 379–382 (1996).
pubmed: 8889910
doi: 10.1097/00004714-199610000-00006
Safarinejad, M. & Hosseini, S. Safety and efficacy of citalopram in the treatment of premature ejaculation: a double-blind placebo-controlled, fixed dose, randomized study. Int. J. Impot. Res. 18, 164–169 (2006).
pubmed: 16107866
doi: 10.1038/sj.ijir.3901384
Atmaca, M., Kuloglu, M., Tezcan, E. & Semercioz, A. The efficacy of citalopram in the treatment of premature ejaculation: a placebo-controlled study. Int. J. Impot. Res. 14, 502–505 (2002).
pubmed: 12494286
doi: 10.1038/sj.ijir.3900918
Waldinger, M. D., Hengeveld, M. W., Zwinderman, A. H. & Olivier, B. Effect of SSRI antidepressants on ejaculation: a double-blind, randomized, placebo-controlled study with fluoxetine, fluvoxamine, paroxetine, and sertraline. J. Clin. Psychopharmacol. 18, 274–281 (1998).
pubmed: 9690692
doi: 10.1097/00004714-199808000-00004
Fallon, B. ‘Off-label’ drug use in sexual medicine treatment. Int. J. Impot. Res. 20, 127–134 (2008).
pubmed: 17851582
doi: 10.1038/sj.ijir.3901610
Machado, M., Iskedjian, M., Ruiz, I. & Einarson, T. R. Remission, dropouts, and adverse drug reaction rates in major depressive disorder: a meta-analysis of head-to-head trials. Curr. Med. Res. Opin. 22, 1825–1837 (2006).
pubmed: 16968586
doi: 10.1185/030079906X132415
Coupland, N. J., Bell, C. J. & Potokar, J. P. Serotonin reuptake inhibitor withdrawal. J. Clin. Psychopharmacol. 16, 356–362 (1996).
pubmed: 8889907
doi: 10.1097/00004714-199610000-00003
Jern, P., Johansson, A., Piha, J., Westberg, L. & Santtila, P. Antidepressant treatment of premature ejaculation: discontinuation rates and prevalence of side effects for dapoxetine and paroxetine in a naturalistic setting. Int. J. Impot. Res. 27, 75–80 (2015).
pubmed: 25410962
doi: 10.1038/ijir.2014.37
Koyuncu, H., Serefoglu, E. C., Ozdemir, A. T. & Hellstrom, W. J. Deleterious effects of selective serotonin reuptake inhibitor treatment on semen parameters in patients with lifelong premature ejaculation. Int. J. Impot. Res. 24, 171–173 (2012).
pubmed: 22573230
doi: 10.1038/ijir.2012.12
Tanrikut, C. & Schlegel, P. N. Antidepressant-associated changes in semen parameters. Urology 69, 185.e185–185.e187 (2007).
doi: 10.1016/j.urology.2006.10.034
Koyuncu, H. et al. Escitalopram treatment for premature ejaculation has a negative effect on semen parameters. Int. J. Impot. Res. 23, 257–261 (2011).
pubmed: 21776003
doi: 10.1038/ijir.2011.35
Akasheh, G., Sirati, L., Noshad Kamran, A. R. & Sepehrmanesh, Z. Comparison of the effect of sertraline with behavioral therapy on semen parameters in men with primary premature ejaculation. Urology 83, 800–804 (2014).
pubmed: 24529582
doi: 10.1016/j.urology.2013.12.004
Relwani, R. et al. Semen parameters are unrelated to BMI but vary with SSRI use and prior urological surgery. Reprod. Sci. 18, 391–397 (2011).
pubmed: 20959643
doi: 10.1177/1933719110385708
Insel, T. R. et al. Obsessive-compulsive disorder. A double-blind trial of clomipramine and clorgyline. Arch. Gen. Psychiatry 40, 605–612 (1983).
pubmed: 6342562
doi: 10.1001/archpsyc.1983.04390010015002
Goodman, R. E. An assessment of clomipramine (Anafranil) in the treatment of premature ejaculation. J. Int. Med. Res. 8 (Suppl. 3), 53–59 (1980).
pubmed: 7193614
Segraves, R. T., Saran, A., Segraves, K. & Maguire, E. Clomipramine versus placebo in the treatment of premature ejaculation: a pilot study. J. Sex. Marital. Ther. 19, 198–200 (1993).
pubmed: 8246275
doi: 10.1080/00926239308404904
Strassberg, D. S., de Gouveia Brazao, C. A., Rowland, D. L., Tan, P. & Slob, A. K. Clomipramine in the treatment of rapid (premature) ejaculation. J. Sex. Marital. Ther. 25, 89–101 (1999).
pubmed: 10327378
doi: 10.1080/00926239908403982
Wu, P. C., Hung, C. S., Kang, Y. N. & Wu, C. C. Tolerability and optimal therapeutic dosage of clomipramine for premature ejaculation: a systematic review and meta-analysis. Sex. Med. 9, 100283 (2021).
pubmed: 33291044
doi: 10.1016/j.esxm.2020.10.011
Boolell, M. et al. Sildenafil: an orally active type 5 cyclic GMP-specific phosphodiesterase inhibitor for the treatment of penile erectile dysfunction. Int. J. Impot. Res. 8, 47–52 (1996).
pubmed: 8858389
Chen, J., Keren-Paz, G., Bar-Yosef, Y. & Matzkin, H. The role of phosphodiesterase type 5 inhibitors in the management of premature ejaculation: a critical analysis of basic science and clinical data. Eur. Urol. 52, 1331–1339 (2007).
pubmed: 17728050
doi: 10.1016/j.eururo.2007.08.005
Krishnappa, P., Fernandez-Pascual, E., Carballido, J. & Martinez-Salamanca, J. I. Sildenafil/Viagra in the treatment of premature ejaculation. Int. J. Impot. Res. 31, 65–70 (2019).
pubmed: 30837718
doi: 10.1038/s41443-018-0099-2
Pfaus, J. G. Neurobiology of sexual behavior. Curr. Opin. Neurobiol. 9, 751–758 (1999).
pubmed: 10607643
doi: 10.1016/S0959-4388(99)00034-3
Aversa, A. et al. Effects of vardenafil administration on intravaginal ejaculatory latency time in men with lifelong premature ejaculation. Int. J. Impot. Res. 21, 221–227 (2009).
pubmed: 19474796
doi: 10.1038/ijir.2009.21
McMahon, C. G. et al. Efficacy of sildenafil citrate (Viagra) in men with premature ejaculation. J. Sex. Med. 2, 368–375 (2005).
pubmed: 16422868
doi: 10.1111/j.1743-6109.2005.20351.x
Polat, E. C., Ozbek, E., Otunctemur, A., Ozcan, L. & Simsek, A. Combination therapy with selective serotonin reuptake inhibitors and phosphodiesterase-5 inhibitors in the treatment of premature ejaculation. Andrologia 47, 487–492 (2015).
pubmed: 24811578
doi: 10.1111/and.12289
Lee, W. K. et al. Comparison between on-demand dosing of dapoxetine alone and dapoxetine plus mirodenafil in patients with lifelong premature ejaculation: prospective, randomized, double-blind, placebo-controlled, multicenter study. J. Sex. Med. 10, 2832–2841 (2013).
pubmed: 23937271
doi: 10.1111/jsm.12287
Sun, Y. et al. Efficacy of PDE5Is and SSRIs in men with premature ejaculation: a new systematic review and five meta-analyses. World J. Urol. 35, 1817–1831 (2017).
pubmed: 28913588
doi: 10.1007/s00345-017-2086-5
Dayer, P., Desmeules, J. & Collart, L. [Pharmacology of tramadol]. Drugs 53 (Suppl. 2), 18–24 (1997).
pubmed: 9190321
doi: 10.2165/00003495-199700532-00006
Lee, C. R., McTavish, D. & Sorkin, E. M. Tramadol. Drugs 46, 313–340 (1993).
pubmed: 7691519
doi: 10.2165/00003495-199346020-00008
Safarinejad, M. R. & Hosseini, S. Y. Safety and efficacy of tramadol in the treatment of premature ejaculation: a double-blind, placebo-controlled, fixed-dose, randomized study. J. Clin. Psychopharmacol. 26, 27–31 (2006).
pubmed: 16415702
doi: 10.1097/01.jcp.0000195110.79027.3f
Bar-Or, D., Salottolo, K. M., Orlando, A., Winkler, J. V. & Group, T. O. S. A randomized double-blind, placebo-controlled multicenter study to evaluate the efficacy and safety of two doses of the tramadol orally disintegrating tablet for the treatment of premature ejaculation within less than 2 minutes. Eur. Urol. 61, 736–743 (2012).
pubmed: 21889833
doi: 10.1016/j.eururo.2011.08.039
Salem, E. A. et al. Original research — ejaculatory disorders: tramadol HCL has promise in on-demand use to treat premature ejaculation. J. Sex. Med. 5, 188–193 (2008).
pubmed: 17362279
doi: 10.1111/j.1743-6109.2006.00424.x
Kaynar, M., Kilic, O. & Yurdakul, T. On-demand tramadol hydrochloride use in premature ejaculation treatment. Urology 79, 145–149 (2012).
pubmed: 22088571
doi: 10.1016/j.urology.2011.09.031
Alghobary, M., El-Bayoumy, Y., Mostafa, Y., Mahmoud, E.-H. M. & Amr, M. Evaluation of tramadol on demand vs. daily paroxetine as a long-term treatment of lifelong premature ejaculation. J. Sex. Med. 7, 2860–2867 (2010).
pubmed: 20367773
doi: 10.1111/j.1743-6109.2010.01789.x
Mittino, D., Mula, M. & Monaco, F. Serotonin syndrome associated with tramadol-sertraline coadministration. Clin. Neuropharmacol. 27, 150–151 (2004).
pubmed: 15190240
doi: 10.1097/00002826-200405000-00012
Takeshita, J. & Litzinger, M. H. Serotonin syndrome associated with tramadol. Prim. Care Companion J. Clin. Psychiatry 11, 273 (2009).
pubmed: 19956471
pmcid: 2781045
doi: 10.4088/PCC.08l00690
Kirby, E. W., Carson, C. C. & Coward, R. M. Tramadol for the management of premature ejaculation: a timely systematic review. Int. J. Impot. Res. 27, 121–127 (2015).
pubmed: 25971856
doi: 10.1038/ijir.2015.7
Waldinger, M. D. Lifelong premature ejaculation: definition, serotonergic neurotransmission and drug treatment. World J. Urol. 23, 102–108 (2005).
pubmed: 15931533
doi: 10.1007/s00345-004-0491-z
Waldinger, M. D. Drug treatment options for premature ejaculation. Expert. Opin. Pharmacother. 19, 1077–1085 (2018).
pubmed: 30028639
doi: 10.1080/14656566.2018.1494725
Park, H. J. et al. Discontinuation of dapoxetine treatment in patients with premature ejaculation: a 2-year prospective observational study. Sex. Med. 5, e99–e105 (2017).
pubmed: 28395997
pmcid: 5440632
doi: 10.1016/j.esxm.2017.02.003
Waldinger, M. D. Lifelong premature ejaculation: from authority-based to evidence-based medicine. BJU Int. 93, 201–207 (2004).
pubmed: 14690484
doi: 10.1111/j.1464-410X.2004.04495.x
Rodgers, R. J. & Cooper, S. J. (eds) 5-HT1A Agonists, 5-HT3 Antagonists and Benzodiazepines: Their Comparative Behavioural Pharmacology (Wiley, 1991).
Andersson, G. & Larsson, K. Effects of FG 5893, a new compound with 5-HT1A receptor agonistic and 5-HT2 receptor antagonistic properties, on male rat sexual behavior. Eur. J. Pharmacol. 255, 131–137 (1994).
pubmed: 8026539
doi: 10.1016/0014-2999(94)90091-4
Haensel, S. M. & Slob, A. K. Flesinoxan: a prosexual drug for male rats. Eur. J. Pharmacol. 330, 1–9 (1997).
pubmed: 9228408
doi: 10.1016/S0014-2999(97)00170-2
Pfaus, J. G. & Heeb, M. M. Implications of immediate-early gene induction in the brain following sexual stimulation of female and male rodents. Brain Res. Bull. 44, 397–407 (1997).
pubmed: 9370204
doi: 10.1016/S0361-9230(97)00219-0
Chéhensse, C. et al. Human spinal ejaculation generator. Ann. Neurol. 81, 35–45 (2017).
pubmed: 27917533
doi: 10.1002/ana.24819
Waldinger, M. D. & Olivier, B. Animal models of premature and retarded ejaculation. World J. Urol. 23, 115–118 (2005).
pubmed: 15940532
doi: 10.1007/s00345-004-0493-x
Jeon, H. J. et al. Candidate molecule for premature ejaculation, DA-8031: in vivo and in vitro characterization of DA-8031. Urology 77, 1006.e1017–1021 (2011).
doi: 10.1016/j.urology.2010.11.046
Kang, K. K. et al. Ejaculatory responses are inhibited by a new chemical entity, DA-8031, in preclinical rodent models of ejaculation. Urology 81, 920.e13–920.e18 (2013).
doi: 10.1016/j.urology.2012.12.006
Kang, K. K., Sung, J. H., Kim, S. H. & Lee, S. Effect of DA-8031, a novel oral compound for premature ejaculation, on male rat sexual behavior. Int. J. Urol. 21, 325–329 (2014).
pubmed: 23968141
doi: 10.1111/iju.12256
Shin, D. et al. Pharmacokinetics and tolerability of DA-8031, a novel selective serotonin reuptake inhibitor for premature ejaculation in healthy male subjects. Drug Des. Dev. Ther. 11, 713 (2017).
doi: 10.2147/DDDT.S126861
US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT01798667 (2013).
Lacivita, E. et al. The therapeutic potential of 5-HT1A receptors: a patent review. Expert Opin. Ther. Pat. 22, 887–902 (2012).
pubmed: 22788968
doi: 10.1517/13543776.2012.703654
US National Library of Medicine. ClinicalTrials.gov https://ClinicalTrials.gov/show/NCT00664365 (2017).
US National Library of Medicine. ClinicalTrials.gov https://ClinicalTrials.gov/show/NCT00861484 (2017).
Migliorini, F. et al. A double-blind, placebo-controlled parallel group study to evaluate the effect of a single oral dose of 5-HT1A antagonist GSK958108 on ejaculation latency time in male patients suffering from premature ejaculation. J. Sex. Med. 18, 63–71 (2021).
pubmed: 33223426
doi: 10.1016/j.jsxm.2020.09.012
Migliorini, F. et al. PD28-08 a double-blind, placebo-controlled parallel group study to evaluate the effect of a single oral dose of GSK958108 on ejaculation latency time in male patients suffering from premature ejaculation. J. Urol. 201, e489–e489 (2019).
doi: 10.1097/01.JU.0000555935.59113.a8
Marcer, A. et al. A double-blind, placebo-controlled parallel group study to evaluate the effect of a single oral dose of GSK958108 on ejaculation latency time in male patients suffering from premature ejaculation. Eur. Urol. Suppl. 18, e1428 (2019).
doi: 10.1016/S1569-9056(19)31030-9
Lyons, T. J. & French, J. Modafinil: the unique properties of a new stimulant. Aviat. Space Environ. Med. 62, 432–435 (1991).
pubmed: 1675850
Ballon, J. S. & Feifel, D. A systematic review of modafinil: potential clinical uses and mechanisms of action. J. Clin. Psychiatry 67, 554–566 (2006).
pubmed: 16669720
doi: 10.4088/JCP.v67n0406
Ferraro, L. et al. Differential enhancement of dialysate serotonin levels in distinct brain regions of the awake rat by modafinil: possible relevance for wakefulness and depression. J. Neurosci. Res. 68, 107–112 (2002).
pubmed: 11933055
doi: 10.1002/jnr.10196
Ferraro, L. et al. Amplification of cortical serotonin release: a further neurochemical action of the vigilance-promoting drug modafinil. Neuropharmacology 39, 1974–1983 (2000).
pubmed: 10963741
doi: 10.1016/S0028-3908(00)00019-8
Regenthal, R., Koch, H., Köhler, C., Preiss, R. & Krügel, U. Depression-like deficits in rats improved by subchronic modafinil. Psychopharmacology 204, 627–639 (2009).
pubmed: 19255746
doi: 10.1007/s00213-009-1493-8
Ferraro, L. et al. Modafinil enhances the increase of extracellular serotonin levels induced by the antidepressant drugs fluoxetine and imipramine: a dual probe microdialysis study in awake rat. Synapse 55, 230–241 (2005).
pubmed: 15668907
doi: 10.1002/syn.20111
Marson, L., Yu, G. & Farber, N. M. The effects of oral administration of d-modafinil on male rat ejaculatory behavior. J. Sex. Med. 7, 70–78 (2010).
pubmed: 19796055
doi: 10.1111/j.1743-6109.2009.01509.x
Serefoglu, E. C. On-demand d-modafinil may be an effective treatment option for lifelong premature ejaculation: a case report. Andrologia 48, 121–122 (2016).
pubmed: 25735219
doi: 10.1111/and.12410
Tuken, M., Kiremit, M. C. & Serefoglu, E. C. On-demand modafinil improves ejaculation time and patient-reported outcomes in men with lifelong premature ejaculation. Urology 94, 139–142 (2016).
pubmed: 27151339
doi: 10.1016/j.urology.2016.04.036
Kawabe, K., Yoshida, M., Homma, Y. & Group, S. C. S. Silodosin, a new α1A-adrenoceptor-selective antagonist for treating benign prostatic hyperplasia: results of a phase III randomized, placebo-controlled, double-blind study in Japanese men. BJU Int. 98, 1019–1024 (2006).
pubmed: 16945121
doi: 10.1111/j.1464-410X.2006.06448.x
Roehrborn, C. G., Kaplan, S. A., Lepor, H. & Volinn, W. Symptomatic and urodynamic responses in patients with reduced or no seminal emission during silodosin treatment for LUTS and BPH. Prostate Cancer Prostatic Dis. 14, 143–148 (2011).
pubmed: 21135869
doi: 10.1038/pcan.2010.46
Chapple, C. R. et al. Silodosin therapy for lower urinary tract symptoms in men with suspected benign prostatic hyperplasia: results of an international, randomized, double-blind, placebo- and active-controlled clinical trial performed in Europe. Eur. Urol. 59, 342–352 (2011).
pubmed: 21109344
doi: 10.1016/j.eururo.2010.10.046
Sato, Y. et al. Silodosin and its potential for treating premature ejaculation: a preliminary report. Int. J. Urol. 19, 268–272 (2012).
pubmed: 22188258
doi: 10.1111/j.1442-2042.2011.02941.x
Bhat, G. S. & Shastry, A. Effectiveness of ‘on demand’ silodosin in the treatment of premature ejaculation in patients dissatisfied with dapoxetine: a randomized control study. Cent. Eur. J. Urol. 69, 280–284 (2016).
Hwang, E. C. et al. Naftopidil for the treatment of lower urinary tract symptoms compatible with benign prostatic hyperplasia. Cochrane Database Syst. Rev. 10, CD007360 (2018).
pubmed: 30306544
Sato, Y. et al. Silodosin versus naftopidil in the treatment of premature ejaculation: a prospective multicenter trial. Int. J. Urol. 24, 626–631 (2017).
pubmed: 28627033
doi: 10.1111/iju.13392
Bhat, G. S. & Shastry, A. A prospective double-blind, randomized, placebo-controlled study to evaluate the efficacy of silodosin 8 mg as an on-demand, reversible, nonhormonal oral contraceptive for males: a pilot study. World J. Urol. 38, 747–751 (2020).
pubmed: 31076850
doi: 10.1007/s00345-019-02806-7
Liu, N., Yang, H., Han, L. & Ma, M. Oxytocin in women’s health and disease. Front. Endocrinol. https://doi.org/10.3389/fendo.2022.786271 (2022).
doi: 10.3389/fendo.2022.786271
de Jong, T. R., Veening, J. G., Olivier, B. & Waldinger, M. D. Oxytocin involvement in SSRI-induced delayed ejaculation: a review of animal studies. J. Sex. Med. 4, 14–28 (2007).
pubmed: 17233773
doi: 10.1111/j.1743-6109.2006.00394.x
Stoneham, M. D., Everitt, B. J., Hansen, S., Lightman, S. L. & Todd, K. Oxytocin and sexual behaviour in the male rat and rabbit. J. Endocrinol. 107, 97–106 (1985).
pubmed: 4045356
doi: 10.1677/joe.0.1070097
Arletti, R., Benelli, A. & Bertolini, A. Sexual behavior of aging male rats is stimulated by oxytocin. Eur. J. Pharmacol. 179, 377–381 (1990).
pubmed: 2364993
doi: 10.1016/0014-2999(90)90178-9
Clement, P. et al. Inhibition of ejaculation by the non-peptide oxytocin receptor antagonist GSK557296: a multi-level site of action. Br. J. Pharmacol. 169, 1477–1485 (2013).
pubmed: 23530818
pmcid: 3724105
doi: 10.1111/bph.12198
Shinghal, R. et al. Safety and efficacy of epelsiban in the treatment of men with premature ejaculation: a randomized, double-blind, placebo-controlled, fixed-dose study. J. Sex. Med. 10, 2506–2517 (2013).
pubmed: 23937679
doi: 10.1111/jsm.12272
Wayman, C. et al. Cligosiban, a novel brain-penetrant, selective oxytocin receptor antagonist, inhibits ejaculatory physiology in rodents. J. Sex. Med. 15, 1698–1706 (2018).
pubmed: 30527053
doi: 10.1016/j.jsxm.2018.10.008
McMahon, C. et al. The oxytocin antagonist cligosiban prolongs intravaginal ejaculatory latency and improves patient-reported outcomes in men with lifelong premature ejaculation: results of a randomized, double-blind, placebo-controlled proof-of-concept trial (PEPIX). J. Sex. Med. 16, 1178–1187 (2019).
pubmed: 31351659
doi: 10.1016/j.jsxm.2019.05.016
Althof, S., Osterloh, I. H., Muirhead, G. J., George, K. & Girard, N. The oxytocin antagonist cligosiban fails to prolong intravaginal ejaculatory latency in men with lifelong premature ejaculation: results of a randomized, double-blind, placebo-controlled phase IIb trial (PEDRIX). J. Sex. Med. 16, 1188–1198 (2019).
pubmed: 31351660
doi: 10.1016/j.jsxm.2019.05.015
Gul, M. & Serefoglu, E. C. Oxytocin antagonists: the next frontier in PE treatment. Nat. Rev. Urol. 16, 696–697 (2019).
pubmed: 31551585
doi: 10.1038/s41585-019-0238-7
David Prologo, J. et al. Percutaneous CT-guided cryoablation of the dorsal penile nerve for treatment of symptomatic premature ejaculation. J. Vasc. Interv. Radiol. 24, 214–219 (2013).
pubmed: 23182939
doi: 10.1016/j.jvir.2012.09.015
Zhang, G. X., Yu, L. P., Bai, W. J. & Wang, X. F. Selective resection of dorsal nerves of penis for premature ejaculation. Int. J. Androl. 35, 873–879 (2012).
pubmed: 22882515
doi: 10.1111/j.1365-2605.2012.01296.x
Zhang, C. Y. et al. [Regional anatomy of the dorsal penile nerve and its clinical significance]. Zhonghua Nan Ke Xue 15, 130–133 (2009).
pubmed: 19323372
Shi, W. G. et al. [Selective resection of the branches of the two dorsal penile nerves for primary premature ejaculation]. Zhonghua Nan Ke Xue 14, 436–438 (2008).
pubmed: 18572864
Liu, Q. et al. Anatomic basis and clinical effect of selective dorsal neurectomy for patients with lifelong premature ejaculation: a randomized controlled trial. J. Sex. Med. 16, 522–530 (2019).
pubmed: 30935469
doi: 10.1016/j.jsxm.2019.01.319
Zhang, H. F., Zhang, C. Y., Li, X. H., Fu, Z. Z. & Chen, Z. Y. Dorsal penile nerves and primary premature ejaculation. Chin. Med. J. 122, 3017–3019 (2009).
pubmed: 20137494
Moon, D. G. et al. Augmentation of glans penis using injectable hyaluronic acid gel. Int. J. Impot. Res. 15, 456–460 (2003).
pubmed: 14671667
doi: 10.1038/sj.ijir.3901058
Kim, J. J., Kwak, T. I., Jeon, B. G., Cheon, J. & Moon, D. G. Effects of glans penis augmentation using hyaluronic acid gel for premature ejaculation. Int. J. Impot. Res. 16, 547–551 (2004).
pubmed: 15057258
doi: 10.1038/sj.ijir.3901226
Kwak, T. I., Jin, M. H., Kim, J. J. & Moon, D. G. Long-term effects of glans penis augmentation using injectable hyaluronic acid gel for premature ejaculation. Int. J. Impot. Res. 20, 425–428 (2008).
pubmed: 18548080
doi: 10.1038/ijir.2008.26
Abdallah, H. et al. Treatment of premature ejaculation by glans penis augmentation using hyaluronic acid gel: a pilot study. Andrologia 44 (Suppl. 1), 650–653 (2012).
pubmed: 22013959
doi: 10.1111/j.1439-0272.2011.01244.x
Alahwany, A., Ragab, M. W., Zaghloul, A., Abdallah, H. & Mostafa, T. Hyaluronic acid injection in glans penis for treatment of premature ejaculation: a randomized controlled cross-over study. Int. J. Impot. Res. https://doi.org/10.1038/s41443-018-0104-9 (2019).
doi: 10.1038/s41443-018-0104-9
pubmed: 30610210
Gul, M. Comment on “Hyaluronic acid injection in glans penis for treatment of premature ejaculation: a randomized controlled cross-over study”. Int. J. Impot. Res. https://doi.org/10.1038/s41443-019-0200-5 (2019).
doi: 10.1038/s41443-019-0200-5
pubmed: 31543515
Ahn, S. T., Il Kwak, T., Park, K. S., Kim, J. J. & Moon, D. G. Complications of glans penis augmentation. Int. J. Impot. Res. 31, 245–255 (2019).
pubmed: 30478264
doi: 10.1038/s41443-018-0097-4
Zhang, C. et al. Efficacy and safety assessment of glandular augmentation with hyaluronic acid for premature ejaculation. Andrologia https://doi.org/10.1111/and.14435 (2022).
doi: 10.1111/and.14435
pubmed: 36285609
pmcid: 9349874
Shebl, S. E., Ali, S. & Shokr, M. Hyaluronic acid injection in the glans penis for the treatment of refractory premature ejaculation: a prospective, controlled study. Andrologia 53, e14084 (2021).
pubmed: 33930204
doi: 10.1111/and.14084
Moon du, G., Kwak, T. I. & Kim, J. J. Glans penis augmentation using hyaluronic acid gel as an injectable filler. World J. Mens. Health 33, 50–61 (2015).
pubmed: 26331121
doi: 10.5534/wjmh.2015.33.2.50
Huang, W., Foster, J. A. & Rogachefsky, A. S. Pharmacology of botulinum toxin. J. Am. Acad. Dermatol. 43, 249–259 (2000).
pubmed: 10906647
doi: 10.1067/mjd.2000.105567
Jankovic, J. Botulinum toxin in clinical practice. J. Neurol. Neurosurg. Psychiatry 75, 951–957 (2004).
pubmed: 15201348
pmcid: 1739107
doi: 10.1136/jnnp.2003.034702
Jost, W. H. & Naumann, M. Botulinum toxin in neuro-urological disorders. Mov. Disord. 19, S142–S145 (2004).
pubmed: 15027067
doi: 10.1002/mds.20068
Serefoglu, E. C. & Silay, M. S. Botulinum toxin-A injection may be beneficial in the treatment of life-long premature ejaculation. Med. Hypotheses 74, 83–84 (2010).
pubmed: 19683401
doi: 10.1016/j.mehy.2009.07.038
Gerstenberg, T. C., Levin, R. J. & Wagner, G. Erection and ejaculation in man. Assessment of the electromyographic activity of the bulbocavernosus and ischiocavernosus muscles. Br. J. Urol. 65, 395–402 (1990).
pubmed: 2340374
doi: 10.1111/j.1464-410X.1990.tb14764.x
Serefoglu, E. C. et al. Effect of botulinum-A toxin injection into bulbospongiosus muscle on ejaculation latency in male rats. J. Sex. Med. 11, 1657–1663 (2014).
pubmed: 24774776
doi: 10.1111/jsm.12553
Ongun, S. et al. Can botulinum-A toxin be used to delay ejaculation: results of an ejaculation model in male rats. J. Sex. Med. 16, 1338–1343 (2019).
pubmed: 31277970
doi: 10.1016/j.jsxm.2019.06.002
US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/show/NCT01917006 (2018).
Li, Z. T. et al. [Injection of botulinum-A toxin into bulbospongiosus muscle for primary premature ejaculation: a preliminary clinical study]. Zhonghua Nan Ke Xue 24, 713–718 (2018).
pubmed: 30173431
Aoki, K. R. J. Pharmacology and immunology of botulinum toxin serotypes. J. Neurol. 248 (Suppl. 1), 3–10 (2001).
pubmed: 11357237
doi: 10.1007/PL00007816
Chermansky, C. J. & Chancellor, M. B. Use of botulinum toxin in urologic diseases. Urology 91, 21–32 (2016).
pubmed: 26777748
doi: 10.1016/j.urology.2015.12.049
Pischedda, A., Fusco, F., Curreli, A., Grimaldi, G. & Farina, F. P. Pelvic floor and sexual male dysfunction. Arch. Ital. Urol. Nefrol. Androl. 85, 1–7 (2013).
doi: 10.4081/aiua.2013.1.1
Screponi, E. et al. Prevalence of chronic prostatitis in men with premature ejaculation. Urology 58, 198–202 (2001).
pubmed: 11489699
doi: 10.1016/S0090-4295(01)01151-7
Pastore, A. L. et al. Pelvic floor muscle rehabilitation for patients with lifelong premature ejaculation: a novel therapeutic approach. Ther. Adv. Urol. 6, 83–88 (2014).
pubmed: 24883105
pmcid: 4003840
doi: 10.1177/1756287214523329
Pastore, A. et al. A prospective randomized study to compare pelvic floor rehabilitation and dapoxetine for treatment of lifelong premature ejaculation. Int. J. Androl. 35, 528–533 (2012).
pubmed: 22320846
doi: 10.1111/j.1365-2605.2011.01243.x
Pastore, A. L. et al. Pelvic muscle floor rehabilitation as a therapeutic option in lifelong premature ejaculation: long-term outcomes. Asian J. Androl. 20, 572–575 (2018).
pubmed: 29974885
pmcid: 6219291
doi: 10.4103/aja.aja_30_18
Gruenwald, I. et al. Transcutaneous neuromuscular electrical stimulation may be beneficial in the treatment of premature ejaculation. Med. Hypotheses 109, 181–183 (2017).
pubmed: 29150283
doi: 10.1016/j.mehy.2017.10.008
Shechter, A. et al. Transcutaneous functional electrical stimulation — a novel therapy for premature ejaculation: results of a proof of concept study. Int. J. Impot. Res. https://doi.org/10.1038/s41443-019-0207-y (2019).
doi: 10.1038/s41443-019-0207-y
pubmed: 31570825
Peyronnet, B., Amarenco, G., Kerdraon, J., Cornu, J. N. & Gamé, X. Transcutaneous posterior tibial nerve stimulation: ready for prime time. Neurourol. Urodyn. 38, 1024–1025 (2019).
pubmed: 30742341
doi: 10.1002/nau.23932
Polat Dunya, C., Tulek, Z., Kürtüncü, M., Panicker, J. N. & Eraksoy, M. Effectiveness of the transcutaneous tibial nerve stimulation and pelvic floor muscle training with biofeedback in women with multiple sclerosis for the management of overactive bladder. Mult. Scler. 27, 621–629 (2021).
pubmed: 32513049
doi: 10.1177/1352458520926666
Giuliano, F. Neurophysiology of erection and ejaculation. J. Sex. Med. 8 (Suppl. 4), 310–315 (2011).
pubmed: 21967393
doi: 10.1111/j.1743-6109.2011.02450.x
Puppo, V. & Puppo, G. Comprehensive review of the anatomy and physiology of male ejaculation: premature ejaculation is not a disease. Clin. Anat. 29, 111–119 (2016).
pubmed: 26457680
doi: 10.1002/ca.22655
Uribe, O. L., Sandoval-Salinas, C., Corredor, H. A., Martínez, J. M. & Saffon, J. P. Transcutaneous electric nerve stimulation to treat patients with premature ejaculation: phase II clinical trial. Int. J. Impot. Res. https://doi.org/10.1038/s41443-019-0196-x (2019).
doi: 10.1038/s41443-019-0196-x
pubmed: 31551577
Aydos, M. M., Nas, I. & Önen, E. The impact of transcutaneous posterior tibial nerve stimulation in patients with premature ejaculation. Eur. Res. J. https://doi.org/10.18621/eurj.565190 (2020).
doi: 10.18621/eurj.565190
US National Library of Medicine. ClinicalTrials.gov https://ClinicalTrials.gov/show/NCT04207723 (2020).
Zavatti, M. et al. Experimental study on Satureja montana as a treatment for premature ejaculation. J. Ethnopharmacol. 133, 629–633 (2011).
pubmed: 21040774
doi: 10.1016/j.jep.2010.10.058
Sansalone, S. et al. A combination of tryptophan, Satureja montana, Tribulus terrestris, Phyllanthus emblica extracts is able to improve sexual quality of life in patient with premature ejaculation. Arch. Ital. Urol. Androl. 88, 171–176 (2016).
pubmed: 27711088
doi: 10.4081/aiua.2016.3.171
Sansalone, S. et al. Alga Ecklonia bicyclis, Tribulus terrestris, and glucosamine oligosaccharide improve erectile function, sexual quality of life, and ejaculation function in patients with moderate mild-moderate erectile dysfunction: a prospective, randomized, placebo-controlled, single-blinded study. Biomed. Res. Int. 2014, 121396 (2014).
pubmed: 25136552
pmcid: 4127274
doi: 10.1155/2014/121396
Cai, T. et al. Rhodiola rosea, folic acid, zinc and biotin (EndEP®) is able to improve ejaculatory control in patients affected by lifelong premature ejaculation: results from a phase I–II study. Exp. Ther. Med. 12, 2083–2087 (2016).
pubmed: 27698696
pmcid: 5038509
doi: 10.3892/etm.2016.3595
Cai, T. et al. The role of diallyl thiosulfinate associated with nuciferine and diosgenin in the treatment of premature ejaculation: a pilot study. Arch. Ital. Urol. Androl. 90, 59–64 (2018).
pubmed: 29633800
doi: 10.4081/aiua.2018.1.59
Saadat, S. H., Ahmadi, K. & Panahi, Y. The effect of on-demand caffeine consumption on treating patients with premature ejaculation: a double-blind randomized clinical trial. Curr. Pharm. Biotechnol. 16, 281–287 (2015).
pubmed: 25601604
doi: 10.2174/1389201016666150118133045
Coste, B. et al. Piezo1 and Piezo2 are essential components of distinct mechanically activated cation channels. Science 330, 55–60 (2010).
pubmed: 20813920
pmcid: 3062430
doi: 10.1126/science.1193270
Chen, Z. et al. Significance of piezo-type mechanosensitive ion channel component 2 in premature ejaculation: an animal study. Andrology 8, 1347–1359 (2020).
pubmed: 32100938
doi: 10.1111/andr.12779
Huang, Y. et al. Expression of brain-derived neurotrophic factor in rapid ejaculator rats: a further study. Andrologia https://doi.org/10.1111/and.14134 (2021).
doi: 10.1111/and.14134
pubmed: 34931337
Miranda, M., Morici, J. F., Zanoni, M. B. & Bekinschtein, P. Brain-derived neurotrophic factor: a key molecule for memory in the healthy and the pathological brain. Front. Cell. Neurosci. https://doi.org/10.3389/fncel.2019.00363 (2019).
doi: 10.3389/fncel.2019.00363
pubmed: 31440144
pmcid: 6692714
Waldinger, M. D. & Schweitzer, D. H. Differences between ICD-11 MMS and DSM-5 definition of premature ejaculation: a continuation of historical inadequacies and a source of serious misinterpretation by some European Regulatory Agencies (PART 2). Int. J. Impot. Res. 31, 310–318 (2019).
pubmed: 30659291
doi: 10.1038/s41443-018-0108-5
Waldinger, M. D. & Schweitzer, D. H. Method and design of drug treatment research of subjective premature ejaculation in men differs from that of lifelong premature ejaculation in males: proposal for a new objective measure (part 1). Int. J. Impot. Res. 31, 328–333 (2019).
pubmed: 30647430
doi: 10.1038/s41443-018-0107-6
Janssen, P. K. C. & Waldinger, M. D. Use of a confirmed mathematical method for back-analysis of IELT distributions: ejaculation time differences between two continents and between continents and men with lifelong premature ejaculation (Part 1). Int. J. Impot. Res. 31, 334–340 (2019).
pubmed: 31391576
doi: 10.1038/s41443-019-0173-4
Janssen, P. K. C. & Waldinger, M. D. Men with subjective premature ejaculation have a similar lognormal IELT distribution as men in the general male population and differ mathematically from males with lifelong premature ejaculation after an IELT of 1.5 minutes (Part 2). Int. J. Impot. Res. 31, 341–347 (2019).
pubmed: 31395985
doi: 10.1038/s41443-019-0172-5